Current market catalysts

XORTX Announces Termination and Postponement of Investor Relations Program

XORTX Therapeutics has terminated its US$2.5 million investor relations and marketing agreement with IR Agency LLC effective August 7, 2026, with all funds returned to the company. The decision was made to postpone the IR program during the company's voluntary delisting from the TSX Venture Exchange, expected to take effect September 1, 2026. The company aims to reduce regulatory complexity and focus resources on clinical development. Additionally, XORTX disclosed previously omitted finder's fees of US$240,000 related to its April 2026 acquisition of Vectus Biosystems' Renal Anti-Fibrotic Therapeutic Program.

SMPL DEADLINE ALERT: RGRD Law Files Class Action Lawsuit Against The Simply Good Foods Company and Announces Opportunity for Investors with Substantial Losses to Lead Investor Class Action Lawsuit Before October 13, 2026 Deadline

Robbins Geller has filed a class action lawsuit against The Simply Good Foods Company, alleging that executives made materially false and misleading statements regarding the OWYN acquisition. The company failed to disclose product quality issues with pea protein formulations, loss of key personnel, and operational integration problems. Stock prices fell 17% in October 2025 and 27% in April 2026 following earnings revelations of OWYN sales declines and a $187 million impairment charge. Investors with substantial losses can seek lead plaintiff status before October 13, 2026.

Needham Maintains Buy on Workday, Raises Price Target to $230

Needham analyst Scott Berg maintains Workday (NASDAQ:WDAY) with a Buy and raises the price target from $180 to $230.

Yext Likely To Report Higher Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Yext (NYSE: YEXT) to release 2nd earnings report on Sept. 1, analysts expect earnings of 17 cents/share and revenue of $111.3 million. Stock gained 4%.

8-K filing — ALTRIA GROUP, INC. (MO)

Filed: 2026-08-28 AccNo: 0000764180-26-000098 Size: 219 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

HC Wainwright & Co. Maintains Buy on Moleculin Biotech, Lowers Price Target to $3

HC Wainwright & Co. analyst Sara Nik maintains Moleculin Biotech (NASDAQ:MBRX) with a Buy and lowers the price target from $22 to $3.

N-Able Board Approves Increase Of $50M To Share Repurchase Program

N-able, Inc. (NYSE:NABL), a global cybersecurity company delivering business resilience, today announced that its Board of Directors has approved an increase of $50 million to the previously authorized share repurchase

Bullish Announces $100M Stablecoin Debt Facility To USD.AI For GPU-Backed AI Infrastructure Financing; Plans To List sUSDai Across Multiple Trading Pairs With Market-Making Program

8-K filing — N-able, Inc. (NABL)

Filed: 2026-08-28 AccNo: 0001834488-26-000051 Size: 177 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Needham Maintains Buy on SentinelOne, Raises Price Target to $26

Needham analyst Mike Cikos maintains SentinelOne (NYSE:S) with a Buy and raises the price target from $20 to $26.

Eli Lilly Says FDA Approves Mounjaro, Dual GIP And GLP-1 Hormone Receptor Agonist, To Lower Risk Of Major Adverse Cardiovascular Events In Adults With Type 2 Diabetes

Mounjaro is the first and only GIP and GLP-1 receptor agonist proven to lower heart attack, stroke or cardiovascular death risk in adults with type 2 diabetes at high risk for these events – in addition to its

Moderna Announces Pricing Of Upsized $2.6B 0.00% Convertible Senior Notes Due 2032; Initial Conversion Price $210.58/Share, A 47.5% Premium, With Capped Call Cap At 175% Premium

HC Wainwright & Co. Reiterates Buy on IREN, Maintains $90 Price Target

HC Wainwright & Co. analyst Mike Colonnese reiterates IREN (NASDAQ:IREN) with a Buy and maintains $90 price target.

Chagee Holdings Q2 Adj. EPS $0.37 Beats $0.32 Estimate, Sales $503.250M Miss $528.290M Estimate

Chagee Holdings (NASDAQ:CHA) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $0.32 by 15.62 percent. This is a 19.57 percent decrease over earnings of $0.46 per share from the

8-K filing — FingerMotion, Inc. (FNGR)

Filed: 2026-08-28 AccNo: 0001493152-26-040492 Size: 290 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

8-K filing — GlobalTech Corp (GLTK)

Filed: 2026-08-28 AccNo: 0001477932-26-005308 Size: 191 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Optimus Just Entered Production at Fremont. Here's What Changes for Tesla Investors.

Tesla has begun Optimus robot production at its Fremont facility, a landmark milestone but not a pivotal moment. While Tesla claims Optimus will represent 80% of the company's future value, scaling production will be extremely challenging due to the need to build an entirely new supply chain. Initial production will follow a flat S-curve with slow growth, and improvements may not be immediately visible in financial metrics as robots are used internally for iterative development.

Inflection Point Acquisition Corp. VIII Announces Pricing of $250 Million Initial Public Offering

Inflection Point Acquisition Corp. VIII, a SPAC, priced its initial public offering of 25 million units at $10.00 per unit on August 27, 2026. Each unit includes one Class A ordinary share and one-third of a redeemable warrant exercisable at $11.50. The company plans to pursue a business combination with a North American or European business in disruptive growth sectors. Trading on Nasdaq is expected to begin August 28, 2026, under ticker symbols IPHXU (units), IPHX (shares), and IPHXW (warrants).

Affirm Holdings (AFRM) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Affirm Holdings reported Q4 2026 revenue of $1.17 billion, up 33% year-over-year and beating consensus estimates by 5.23%. EPS of $4.62 significantly exceeded the $0.33 estimate. Key metrics including GMV, interest income, and loan sale gains all met or exceeded analyst expectations. The stock has a Zacks Rank #3 (Hold) rating.

Cygnus Metals Limited : Mise à jour des résultats de forage

Cygnus Metals announced positive exploration results from its Chibougamau copper-gold project in Quebec. At Copper Rand, drilling returned 20.3m at 4.2 g/t AuEq, while at Gwillim, all nine drill holes intersected gold mineralization with highlights including 13.5m at 8.0 g/t Au. The company is advancing three deposits within 3km of a centralized processing facility with combined resources of 545 koz AuEq (indicated and inferred).

Ulta (ULTA) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Ulta Beauty reported $3.04 billion in revenue for Q2 2026, up 8.9% year-over-year and exceeding the consensus estimate of $2.97 billion by 2.1%. EPS came in at $6.55 versus $6.21 expected, representing a 5.48% surprise. Comparable sales grew 3.8% versus the 2% estimate, with strong performance in haircare (+20%) and fragrance (+13%) categories. The company opened 14 new stores during the quarter. Ulta's stock has gained 6.9% over the past month and currently holds a Zacks Rank #3 (Hold) rating.

Cygnus Metals Limited: Drilling Results Update

Cygnus Metals announced positive exploration results from its Chibougamau Copper-Gold Project in Quebec. Drilling at Copper Rand returned intersections including 20.3m at 4.2g/t AuEq, while the maiden drill program at Gwillim intersected gold mineralization in all nine holes with highlights of 13.5m at 8.0g/t Au. The three deposits (Copper Rand, Cedar Bay, and Golden Eye) are located within 3km of a central processing facility, supporting a hub-and-spoke development model.

CRTO INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Criteo S.A.

Law firm Kirby McInerney LLP is investigating Criteo S.A. for potential federal securities law violations following the company's August 5, 2026 earnings report showing an 11% revenue decline and 49% net income decline year-over-year. The announcement of a new CFO appointment triggered a 24% stock price drop to $17.05. No lawsuit has been filed yet, and the investigation is ongoing.

PLAB IMPORTANT DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Photronics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 4 Deadline in Securities Class Action – PLAB

Rosen Law Firm has filed securities class action lawsuits against Photronics, Inc., UWM Holdings Corporation, and Cogent Communications Holdings, Inc. The firm is seeking lead plaintiffs with losses exceeding $100,000. The Photronics lawsuit alleges the company made false statements about its product pipeline and demand stability, while concealing a critical bottleneck in design releases. Investors have until September 4, 2026 to join the class action.

HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma

HUTCHMED received conditional approval from China's NMPA for ATLED® (fanregratinib), a selective FGFR 1/2/3 inhibitor, for treating advanced intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements in previously treated patients. The Phase II trial demonstrated an objective response rate of 42.5%, median PFS of 6.9 months, and median OS of 16.6 months, addressing a significant therapeutic gap in this aggressive cancer type.

C3.ai vs. Oracle: Which Artificial Intelligence Stock Is a Better Investment in 2026?

The article compares C3.ai and Oracle as AI investment options. C3.ai, focused on enterprise AI software, experienced a 35.7% revenue decline in FY2026 and posted a net loss of $470.4 million, though it maintains a strong balance sheet with zero debt. Oracle, an AI infrastructure provider, grew revenue 17.4% to $67.4 billion with a 25.4% net margin and $638 billion in remaining performance obligations. The author recommends Oracle as the stronger investment due to consistent revenue growth and future guidance of $90 billion in FY2027 sales, while C3.ai must prove it can recover from recent challenges.

CrowdStrike vs. Okta: Which Cybersecurity Stock Is the Better Buy After Q2 Earnings?

Both CrowdStrike and Okta exceeded Q2 expectations and raised guidance, with CRWD surging 20% and OKTA soaring 30%. However, CrowdStrike's valuation has become stretched at 150X forward earnings compared to Okta's 76X. While CrowdStrike showed stronger growth, Okta offers better value with improving margins, robust cash flow, and a more reasonable valuation, earning a Zacks Rank #2 (Buy) versus CRWD's Rank #3 (Hold).

Why Hormel Foods Stock Swooned by 10% Today

Hormel Foods stock plummeted 10% after the company missed revenue expectations ($2.96B vs. $3.05B consensus), cut full-year net sales guidance to $12.1-$12.2B from $12.2-$12.5B, and reported a 7% drop in sales volume. While the company beat earnings per share estimates ($0.37 vs. $0.35 consensus), investors were unforgiving due to weak consumer demand, lower commodity-based pricing, and the company's already-eroded stock performance.

Why Wendy's Stock Dropped Today

Wendy's stock fell 13.55% after reports that billionaire Nelson Peltz's Trian Fund Management will not pursue a takeover bid for the struggling fast-food chain. Despite holding a 16% stake, Trian decided against the acquisition, citing poor performance and an uncompelling valuation. The company faces significant headwinds with global systemwide sales down 6.5% and U.S. same-store sales declining 7% in Q2. New CEO Bob Wright now bears the responsibility of executing a turnaround without the prospect of external acquisition.

WIX FINAL DEADLINE: ROSEN, A LONGSTANDING FIRM, Encourages Wix.com Ltd. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – WIX

Rosen Law Firm announced multiple securities class action lawsuits with upcoming deadlines. The primary case involves Wix.com Ltd., where investors who purchased securities between February 19, 2025 and May 12, 2026 may be eligible for compensation. The lawsuit alleges Wix made false statements about its AI product offerings, overstating competitiveness and performance while understating development costs. The lead plaintiff deadline is September 22, 2026. Similar class actions were also filed against Microvast Holdings, Inc. and Photronics, Inc.